Seems to me that the company is in a position of strength assuming the data comes out good. We can start generating revenue under CLIA with or without a partner. If an offer is not to their liking, they don't have to take it but they can still generate revenue. That's how I read the situation anyways.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links